In addition to chairing Bicycle’s Board of Directors, Pierre Legault, MBA, CPA, is the Chairman of Poxel, a biopharmaceutical company developing innovative drugs for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis. He is chairman of Artios, a DNA damage repair company. Pierre is also a member of the board of directors of Clementia Pharmaceuticals, Urovant Sciences and Syndax Pharmaceuticals. In the past, he was a member of the board of directors at Forest Laboratories, Tobira Therapeutics, NPS Pharmaceuticals, Regado Biosciences, Armo Biosciences, Iroko Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy and Nephrogenex, where he also served as the chairman and chief executive officer from 2012 to 2016. From 2010 to 2012, Pierre served as the CEO of Prosidion. From 2009 to 2010, he served as the CFO and treasurer of OSI Pharmaceuticals. Pierre also served as the CEO of Eckerd Pharmacy and senior executive vice president and CAO of Rite Aid Corporation. Between 1989 and 2005, he held various global roles such as president, CEO and CFO of global group at Sanofi and legacy companies.
Pierre studied at McGill University, HEC Montreal and Harvard Business School.